[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,66,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100424396","phase-1-alphabeta-t-cell-depleted-blood-forming-stem-cell-transplant-from-related-or-unrelated-donors-for-blood-diseases-in-children-and-young-adults-100424396",false,"NCT04806347","Alpha\u002FBeta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults","TCRαβ+ and CD19+ Depleted Hematopoietic Stem Cell Transplant From Closely Matched Unrelated Donors or Haploidentical Related Donors for Hematologic Diseases in Children and Young Adults","Inclusion Criteria:\n\n* No Human leukocyte antigen (HLA) identical sibling available AND\n* NO HLA matched unrelated donor available OR urgent need of HSCT precludes time necessary to search for suitable HLA matched unrelated donor AND\n* Haploidentical donor OR closely matched unrelated donor available and willing to undergo mobilization and apheresis\n* If subject has genetically confirmed inherited bone marrow failure, related donor must be evaluated for this disorder and testing must be negative.\n* If subject has sickle cell disease, donor must be unaffected or have only sickle cell trait\n* Patient must be diagnosed with one of the following diseases or disorders:\n\n  * Hemoglobinopathies\n\n    * Sickle Cell Disease for patients ≤ 21 years of age for whom hydroxyurea has been trialed for at least six months, and failed\n    * Thalassemia Major for patients ≤ 21 years of age\n  * Acquired Bone Marrow Failure Syndromes\n\n    * Paroxysmal Nocturnal Hemoglobinuria with bone marrow failure\n    * Myelodysplastic Syndromes (lower risk)\n    * Severe acquired aplastic anemia\n  * Inherited Bone Marrow Failure Syndromes\n\n    * Fanconi Anemia\n    * Diamond Blackfan Anemia\n    * Dyskeratosis Congenita and related telomere disorders\n    * Congenital Thrombocytopenia Syndromes\n    * Severe Congenital Neutropenia\n    * Shwachman-Diamond Syndrome\n  * Inborn Errors of Immunity (IEI) or Primary Immune Regulatory Disorders (PIRD)\n\n    * Wiskott-Aldrich syndrome (WAS)\n    * Chronic granulomatous disease (CGD)\n    * Severe combined immunodeficiency (SCID)\n    * Primary hemophagocytic lymphohistiocytosis (HLH)\n* Age ≤ 25 years (except patients with hemoglobinopathies)\n* Life Expectancy ≥ 3 months\n* Karnofsky (patients \\> 16 years)\u002FLansky (patients ≤ 16 years) index ≥ 60\n* Organ Function Requirements\n\n  * Renal Function\n\n    * Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) greater than or equal to 60 ml\u002Fmin\u002F1.73m\\^2\n  * Liver Function\n\n    * Total bilirubin \\\u003C 3 mg\u002FdL\n    * Alanine aminotransferase (ALT)\u002F Serum glutamic-pyruvic transaminase; synonymous with ALT (SCPT) ≤ 3 x Upper Limit of Normal (ULN) for age\n  * Cardiac Function\n\n    * Ejection fraction of \\> 40% by Multiple gated acquisition scan (MUGA) or echocardiogram\n  * Pulmonary Function\n\n    * No evidence of dyspnea at rest\n    * No supplemental oxygen requirement\n    * If measured, carbon monoxide diffusion capacity (DLCO) \\> 50%\n* Willing to use effective birth control method if patient is of reproductive potential\n* Informed consent obtained (patient or legal representative)\n\nExclusion Criteria:\n\n* Pregnant\n* HIV infection\n* Uncontrolled, serious active infection at screening\n* Significant serious intercurrent illnesses\n* Enrollment in any other treatment study that would interfere with the endpoints of this study according to judgement of Principal Investigator (or PI designee).","ALL","3 Months","25 Years",{"count":20,"type":21},12,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This study is being done to see if the investigators can take peripheral blood stem cells from either an adult family member or a closely matched unrelated donor, and run them through a special lab instrument to remove alpha\u002Fbeta T cells and B cells and then give them to the patient to treat disease. This is an experimental way of doing a hematopoietic stem cell transplant (HSCT). The investigators want to see if the new stem cells will grow without bad graft vs. host disease (GVHD). This treatment approach is experimental in the United States.",[27],"Blood Disease","NOT_YET_RECRUITING","2026-06-29",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-07",{"date":36,"type":21},"2030-05",{"name":38,"class":39},"University of Wisconsin, Madison","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100065664","diamond-blackfan-anemia-registry-dbar-100065664","NCT00106015","Diamond Blackfan Anemia Registry (DBAR)","DBAR","Inclusion Criteria:\n\n* Patients must meet the diagnostic criteria for DBA which include the following:\n\n  1. Normochromic, usually macrocytic and occasionally normocytic anemia developing early in childhood\n  2. Reticulocytopenia\n  3. Normocellular bone marrow with a selective deficiency of red cell precursors\n  4. Normal or slightly decreased leukocyte count\n  5. Normal or often increased platelet count\n  6. Or, a confirmed mutation in one of the identified DBA genes\n\nExclusion Criteria:\n\n* Any subject identified as having another bone marrow failure syndrome (eg. Fanconi anemia, dyskeratosis congenita, Shwachman Diamond syndrome, etc.) will be excluded.",{"count":48,"type":21},900,"OBSERVATIONAL","The purpose of this study is to maintain a comprehensive registry of patients with the rare inherited bone marrow failure syndrome Diamond Blackfan anemia (DBA).",[52,27],"Anemia",[54],"inherited pure red cell aplasia","RECRUITING","2026-04-13",{"date":58,"type":32},"2026-04-16",{"date":60,"type":32},"2004-09",{"date":62,"type":21},"2030-04",{"name":64,"class":39},"Northwell Health",1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100554410","role-of-transcranial-doppler-and-magnetic-resonance-angiography-for-future-management-of-sickle-cell-anemia-cns-100554410","NCT06498726","Role of Transcranial Doppler and Magnetic Resonance Angiography for Future Management of Sickle Cell Anemia CNS.","Inclusion Criteria:\n\n* (1) age, from 24 months to 18 years; (2) hemoglobinopathy diagnosis of Hb SS; (3) the desire and ability to be screened as evidenced by signed parental informed consent and child's assent; (4) the availability for follow-up for at least 2 years.\n\nExclusion Criteria:\n\n\\- 1.Other sickle cell syndromes were excluded because they had a lower or uncertain risk of stroke.\n\n2.A child was excluded from TCD screening for any of the following: an indication for chronic blood transfusion or a contraindication to chronic transfusion, participation in any study involving treatments which might confound the interpretation of the results of the proposed work","2 Years","18 Years",{"count":75,"type":21},18,"This study aimed to determine the Predictive Value of Transcranial Doppler and Magnetic Resonance Angiography for Future Management of Sickle Cell Anemia.\n\nSpecific aims are:\n\nDemonstrate silent parenchymal and vascular brain changes that are incidentally observed in neurologically free SCD children using screening TCD and MRA in Pediatric Hematology unit at Assiut University Hospital\n\nDetect any abnormality with vasculopathy, arterial occlusion and old SCI. Strokes in children with SCD can be prevented by checking a transcranial Doppler (TCD) ultrasound,MRA and providing blood transfusions to children with abnormal blood flow on the TCD and detect Silent cerebral and cerebrovascular changes in SCD.",[27,78],"Brain Injuries","2024-07-07",{"date":81,"type":32},"2024-07-12",{"date":83,"type":21},"2024-09-01",{"date":85,"type":21},"2025-10-01",{"name":87,"class":39},"Eman Abdul-Hai",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":16,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":49,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":119},"100350911","collection-and-distribution-of-biospecimens-for-novel-research-uses-100350911","NCT03848962","Collection and Distribution of Biospecimens for Novel Research Uses","iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research Uses","Inclusion Criteria:\n\n* Individual is developmentally aged 7 years old and above for RUO collections (only)\n* Individual meets requirements of a current request for research materials from iSpecimen\n* If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and\u002For the review of an updated medical history as provided by the participant\n* Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf.\n* Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent\u002Fguardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf\n\nExclusion Criteria:\n\n* Subjects that do not meet the inclusion criteria outlined above.",true,"1 Month","89 Years",{"count":99,"type":21},10000,"iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations (\"institutions\") capable of providing researchers and educators (\"researchers\") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively \"research\").",[102,103,104,105,106,107,108,27],"Cancer","Healthy","Gastrointestinal Complication","Autoimmune Diseases","Infectious Disease","Women's Health: High-Risk Pregnancy","Dermatologic Disease","2022-11-08",{"date":111,"type":32},"2022-11-09",{"date":113,"type":32},"2016-06-30",{"date":115,"type":21},"2026-12-31",{"name":117,"class":118},"iSpecimen Inc","INDUSTRY",2]